GRTX Key Statistics, Chart & Performance
The current stock price of GRTX is 0.145 USD. In the past month the price decreased by -22.04%. In the past year, price decreased by -95.51%.
GRTX Technical Analysis
GRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GRTX. Both the profitability and financial health of GRTX have multiple concerns.
GRTX Financial Highlights
Over the last trailing twelve months GRTX reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 55.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -232.8% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
GRTX Forecast & Estimates
7 analysts have analysed GRTX and the average price target is 0.38 USD. This implies a price increase of 163.79% is expected in the next year compared to the current price of 0.145.
GRTX Ownership
GRTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRTX
Company Profile
Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 31 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. The company has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
Company Info
GALERA THERAPEUTICS INC
45 Liberty Blvd., Suite 230
Malvern PENNSYLVANIA 19355 US
CEO: J. Mel Sorensen
Employees: 31
Phone: 16107251500
GALERA THERAPEUTICS INC / GRTX FAQ
What does GALERA THERAPEUTICS INC do?
Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 31 full-time employees. The company went IPO on 2019-11-07. The firm is focused on developing and commercializing a pipeline of therapeutic candidates to transform radiotherapy in cancer. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic in development for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) and for the reduction of esophagitis in patients with lung cancer. The company has completed Phase III Reduction in Oral Mucositis with Avasopasem Manganese (ROMAN) trial of GC4419 for the reduction of radiotherapy-induced SOM in patients with locally advanced HNC. Its second dismutase mimetic product candidate, rucosopasem manganese (GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and locally advanced pancreatic cancer (LAPC).
What is the current price of GRTX stock?
The current stock price of GRTX is 0.145 USD. The price decreased by -32.59% in the last trading session.
Does GRTX stock pay dividends?
GRTX does not pay a dividend.
How is the ChartMill rating for GALERA THERAPEUTICS INC?
GRTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of GALERA THERAPEUTICS INC (GRTX)?
GALERA THERAPEUTICS INC (GRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
How many employees does GALERA THERAPEUTICS INC have?
GALERA THERAPEUTICS INC (GRTX) currently has 31 employees.